FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Kleiner Perkins Caufield & Byers XV, LLC
2. Date of Event Requiring Statement (Month/Day/Year)
10/15/2014
3. Issuer Name and Ticker or Trading Symbol
Atara Biotherapeutics, Inc. [ATRA]
(Last)
(First)
(Middle)
2750 SAND HILL ROAD
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MENLO PARK, CA 94025
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 746,923
D (1)
 
Common Stock 22,307
D (2)
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock   (3)   (3) Common Stock 1,244,871 $ (3) D (1)  
Series B Preferred Stock   (3)   (3) Common Stock 607,234 $ (3) D (1)  
Series A Preferred Stock   (3)   (3) Common Stock 37,179 $ (3) D (2)  
Series B Preferred Stock   (3)   (3) Common Stock 18,136 $ (3) D (2)  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kleiner Perkins Caufield & Byers XV, LLC
2750 SAND HILL ROAD
MENLO PARK, CA 94025
    X    
KPCB XV Founders Fund, LLC
2750 SAND HILL ROAD
MENLO PARK, CA 94025
    X    
KPCB XV Associates, LLC
2750 SAND HILL ROAD
MENLO PARK, CA 94025
    X    

Signatures

/s/ Paul Vronsky, General Counsel 10/15/2014
**Signature of Reporting Person Date

/s/ Paul Vronsky, General Counsel 10/15/2014
**Signature of Reporting Person Date

/s/ Paul Vronsky, General Counsel 10/15/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB XV Associates, LLC ("XV Associates"). The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
(2) The shares are directly held by KPCB Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
(3) Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into one share of Common Stock without payment of further consideration and will automatically convert into one share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
 
Remarks:
KPCB XV Associates and its respective managing members disclaim beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that any of them is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.